Altre lingue Tempest Therapeutics, Inc.

Azioni

TPST

US87978U1088

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
3,54 ^USD	+1,72%		+14,19%	-19,55%

09/04	Tempest Therapeutics, Inc. riferisce nuovi dati preclinici per TPST-1120 nell'RCC al Meeting Annuale dell'AACR	CI
04/04	Tempest Therapeutics, Inc. annuncia la pubblicazione di dati positivi dello studio di Fase 1 di TPST-1120 in pazienti con tumori solidi avanzati nel Journal of Cancer Research Communications	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	26/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	10/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	09/04
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics : Corporate Presentation - April 2024	29/03
Tempest Therapeutics : Corporate Presentation - March 2024	22/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	20/03
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	19/03
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K	19/03
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	14/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting	05/03
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tempest Therapeutics, Inc.

Azioni

TPST

US87978U1088

Altre lingue

Filtri